Search

THERAVANCE BIOPHARMA REPORTS DATA FROM PHASE 1B STUDY OF TD-1473 IN ORAL PRESENTATION AT DIGESTIVE DISEASE WEEK 2019

Data Demonstrate Signals of Clinical, Histologic and Biomarker Activity Suggesting Localized Target Engagement following Four Weeks...

CMS delays national coverage determination for CAR-T therapies

CMS DELAYS NATIONAL COVERAGE DETERMINATION FOR CAR-T THERAPIES

In a statement, the agency said that a decision on whether to have Medicare cover the cell therapies would not be issued Friday, but...

 
 
 
A Philadelphia story: Read about this gene therapy company's journey from spinout to acquisition

A PHILADELPHIA STORY: READ ABOUT THIS GENE THERAPY COMPANY'S JOURNEY FROM SPINOUT TO ACQUISITION

A company's journey from launch to acquisition is rarely a straight path. It involves overcoming many challenges and obstacles, especially...

States allege price-fixing conspiracy in suit against generic drugmakers

STATES ALLEGE PRICE-FIXING CONSPIRACY IN SUIT AGAINST GENERIC DRUGMAKERS

More than three dozen states and Puerto Rico are part of the lawsuit, against Teva and more than a dozen generic manufacturers, alleging...

 
 
 
BMS's immunotherapy drug Opdivo fails in Phase III brain cancer study

BMS'S IMMUNOTHERAPY DRUG OPDIVO FAILS IN PHASE III BRAIN CANCER STUDY

The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat...

NITTO BIOPHARMA, INC: RESEARCH ASSOCIATE

Nitto BioPharma, Inc: The successful candidate will join our research team as a critical team member to be involved in drug discovery...

 
 
 
Opportunities and pitfalls in the healthcare investment landscape: A conversation with McDermott's Brian Bunn

OPPORTUNITIES AND PITFALLS IN THE HEALTHCARE INVESTMENT LANDSCAPE: A CONVERSATION WITH MCDERMOTT'S BRIAN BUNN

Brian Bunn, a partner with international law firm McDermott Will and Emery, shared his perspective on healthcare investment in the...

Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs

ARRAKIS SPICES UP DEVELOPMENT EFFORTS WITH $75M SERIES B ROUND FOR RNA-TARGETING DRUGS

The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting...

 
 
 

SABPA EVENT: SAN DIEGO BIOPHARMA CONF: JUN 08, 2019

Details and registration here From Jun 08, 2019 12:00AM to Jun 09, 2019 12:00AM at Hilton San Diego/Del Mar, 15575 Jimmy Durante Blvd,...

Roche Lifts Full Year Outlook, Sees Higher Dividend Following ‘Strong' First Quarter Sales

ROCHE LIFTS FULL YEAR OUTLOOK, SEES HIGHER DIVIDEND FOLLOWING ‘STRONG' FIRST QUARTER SALES

Swiss drugmaker Roche said early Wednesday that it started the year with “strong” sales growth in the first quarter, driven by newly...

 
 
 
San Diego Life Sciences Roundup: Evofem, Cullgen, BrainLeap & More

SAN DIEGO LIFE SCIENCES ROUNDUP: EVOFEM, CULLGEN, BRAINLEAP & MORE

Locally based biotech companies receive fresh funding from investors. A software startup launches games that it says may help children...

The Best Places to Work in Health Care and Biopharma

THE BEST PLACES TO WORK IN HEALTH CARE AND BIOPHARMA

Texas Health Resources tops the list of best health care companies once again, while AbbVie moves up to the top of the biopharma list...

 
 
 
Reveal Biosciences Gets Intel's Backing on “AI-Powered” Pathology

REVEAL BIOSCIENCES GETS INTEL'S BACKING ON “AI-POWERED” PATHOLOGY

A 25-person startup developing advanced computing tools to speed up pathology work has raised its first institutional financing from...

Gilead, Galapagos's filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain

GILEAD, GALAPAGOS'S FILGOTINIB SCORES IN PHASE III RHEUMATOID ARTHRITIS TRIAL, BUT QUESTIONS REMAIN

Whether the FDA requires completion of a study to look at testicular toxicity before approval could dictate whether the drug launches...

 
 
 
BIO Urges USTR To Take Action on Growing IP Barriers in Overseas Markets

BIO URGES USTR TO TAKE ACTION ON GROWING IP BARRIERS IN OVERSEAS MARKETS

BIO recently submitted its Special 301 Submission highlighting intellectual property challenges around the world. In particular, BIO...

Biogen's Alzheimer's disease drug crashes in Phase III testing

BIOGEN'S ALZHEIMER'S DISEASE DRUG CRASHES IN PHASE III TESTING

The news sent Biogen's shares down more than 26 percent pre-market, but analysts also wrote that it deals a significant blow to amyloid...

 
 
 
Flagship Pioneering raises $824M in new fund

FLAGSHIP PIONEERING RAISES $824M IN NEW FUND

The venture capital firm had originally set out to raise $700 million for the Special Opportunities Fund II, according to an SEC filing...

FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

 
 
 
Genfit, developing drugs for NASH, to trade on Nasdaq

GENFIT, DEVELOPING DRUGS FOR NASH, TO TRADE ON NASDAQ

The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares...

Report: College bribery scandal tip stemmed from pharma pump-and-dump investigation

REPORT: COLLEGE BRIBERY SCANDAL TIP STEMMED FROM PHARMA PUMP-AND-DUMP INVESTIGATION

The Wall Street Journal reported that Morrie Tobin tipped off investigators about the college bribery scheme, which ensnared a biotech...